by [email protected] | May 5, 2023 | Hematology, Publication
Abstract Background: This study retrospectively compared annualized billed bleed rates (ABRb) in people with hemophilia A (PwHA) without inhibitors who switched from factor VIII (FVIII) prophylaxis to emicizumab. Research design and methods: A real-world comparison...
by [email protected] | Dec 12, 2022 | Publication, Pulmonary
Abstract Background: Mycobacterium avium complex lung disease (MAC-LD) is an infection that is increasing in frequency, associated with substantial disease burden, and often refractory to treatment. Amikacin liposome inhalation suspension (ALIS) is the first therapy...
by [email protected] | Dec 9, 2022 | Publication, Pulmonary
Abstract BACKGROUND: Asthma is a common chronic respiratory disorder associated with significant disease and economic burden. Mepolizumab is an anti-IL-5 mAb approved for use as an add-on treatment in patients with severe eosinophilic asthma. OBJECTIVE: To assess the...
by [email protected] | Dec 9, 2022 | Cardiovascular, Publication
Abstract Background: Oral anticoagulants (OACs) mitigate stroke and systemic embolism (SE) risk in non-valvular atrial fibrillation (AF) patients but can increase the risk of major bleeding (MB). This study analyzed the gains in event-free time for these...
by [email protected] | Dec 9, 2022 | Cardiovascular, Publication
Abstract This study evaluated effectiveness and safety of apixaban versus warfarin among venous thromboembolism patients at high-risk of bleeding (defined as having at least one of the following bleeding risk factors: ≥75 years; used antiplatelet, NSAIDs, or...
by [email protected] | Dec 9, 2022 | Cardiovascular, Publication
Abstract Importance: The CHA2DS2-VASc score (calculated as congestive heart failure, hypertension, age 75 years and older, diabetes, stroke or TIA, vascular disease, age 65 to 74 years, and sex category) is the standard for assessing risk of stroke and systemic...